Is Heart Team Fundamental to Aortic Stenosis Transcatheter Treatment?

DOI: 10.5935/abc.20140060 Demographic projections have shown that the contingent of elderly people in Brazil will double within the next 20 years1, with a consequent increase in the prevalence of aging-related diseases, such as degenerative aortic valve stenosis (AoS), diagnosed in 3% to 5% of the population older than 75 yeas2,3. New modalities of treatment for AoS have been recently developed, mainly represented by the transcatheter implantation of aortic prosthesis (TAVI – Transcatheter Aortic Valve Implantation), which has become a therapeutic option for patients whose conventional surgical treatment is not feasible. In the current scenario, characterized by the high demand of the increasing elderly population, the availability of new treatment methods provides clinical expertise for the accurate diagnosis of heart valve disease, assessment of the comorbidities and risks of interventions, in addition to the rationalization of resources, considering the complexity and high costs involved in TAVI.